Shanghai, China (August 21, 2013) - The first patient implants of the Boston Scientific Corporation (NYSE: BSX) COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) were successfully performed in China’s Zhejiang province and Beijing by Professor Farong Shen in Zhejiang Lucheng Hospital and Professor Wei Hua in Beijing Fuwai Hospital. These events mark the launch of the COGNIS CRT-D in the Chinese market.
Cardiac resynchronization therapy is a treatment option for some heart failure patients that can help the heart pump more efficiently. A CRT-D system can also defibrillate the heart when an arrhythmia occurs.
COGNIS offers Electronic Repositioning™, with six pacing configurations, to manage high pacing thresholds and unwanted diaphragmatic muscle stimulation. SmartDelay® AV Optimization provides individualized therapy without the need for a time-consuming echocardiogram. COGNIS also offers HF Perspectiv™, a proprietary suite of diagnostics, including Heart Rate Variability Footprint® which gives clinicians an objective view of patients’ response to therapy. These features are paired with three left ventricular leads designed to reach and remain in the target vessel. Boston Scientific ENDOTAK RELIANCE® defibrillation leads have a 98.5 percent survival probability at 10 years, the highest in the industry.
The COGNIS CRT-D is the thinnest in the world with exceptional longevity. COGNIS battery technology is the culmination of seven years of research and is unique to Boston Scientific. The projected life expectancy of COGNIS products reaches more than eight years, which is much longer than similar CRT-Ds on the market. Longer-lasting CRT-Ds may significantly reduce the risk of a secondary operation and lessen the financial burden incurred from device replacement.
As for the first implantation of COGNIS in China, Professor Shu Zhang, chairman of the Chinese Cardiac Pacing and Electrophysiology Society and director of the Cardiac Arrhythmias Treatment Center of Beijing Fuwai Hospital, said, “The successful introduction of COGNIS CRT-D once again demonstrates that Boston Scientific, a leading enterprise in the pacing and electrophysiology industry, introduces advanced medical technologies and products.”
Professor Wei Hua, chief physician of cardiovascular department in Fuwai Hospital, also commented, “The Boston Scientific CRT-D System provides clinicians with many implantation choices, including different forms of the left ventricular lead, which I believe drive a high success rate of CRT-D implantation.”
“COGNIS is small and thin, but it has a long service life,” said Professor Farong Shen, executive hospital director and head of the cardiology center in Lucheng Hospital. “I believe that it is indeed a groundbreaking CRT-D product for patients.”
About Boston Scientific in China
In 1997, Boston Scientific established a headquarters in China. Now it has a Research and Development center and branch offices in Beijing, Shanghai, and Guangzhou, providing advanced less-invasive medical products and services to its customers and patients. Core businesses in China include Interventional Cardiology, Cardiac Rhythm Management, Endoscopy and Peripheral Intervention. Through the introduction of innovative ideas and advanced technology, clinical research and medical professional knowledge training, and actively participating in the development of China's health care system, the company strives for providing effective and innovative healthcare solutions for patients. For more information, please visit our website at: http://www.bostonscientific.com/china/index.html
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans in China, markets for our products and our position in those markets, new product launches, product performance and impact, and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
(8621) 6141 5959 (office)
PR and Communications
Boston Scientific China
(8621) 5383 1188 ext. 855 (office)